Assessment of Acute Episodes in Chronic Stable Angina: A Clinical-Laboratory Approach to the Use of the Coronary Vasodilator Propatyl Nitrate

作     者：Gerson Goldwasser Renato Kaufman Carlos Pereira Nunes Alexandre Hid Stephanie Wrobel Goldberg Alessandra Santos Lisa Oliveira Adenilson de Souza da Fonseca Mauro Geller Gerson Goldwasser;Renato Kaufman;Carlos Pereira Nunes;Alexandre Hid;Stephanie Wrobel Goldberg;Alessandra Santos;Lisa Oliveira;Adenilson de Souza da Fonseca;Mauro Geller

作者机构：Souza Marques Medical School Rio de Janeiro Brazil Universidade Estadual do Rio de Janeiro Rio de Janeiro Brazil UNIFESO Medical School Teresópolis Brazil Washington University School of Medicine St. Louis MO USA 

出 版 物：《World Journal of Cardiovascular Diseases》 (心血管病（英文）)

年 卷 期：2016年第6卷第7期

页      面：246-252页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Propatyl Nitrate Stable Chronic Angina Pectoris Seattle Angina Questionnaire 

摘      要：Background/Objectives: Propatyl nitrate is a coronary vasodilator with immediate and prolonged action, indicated in the treatment and prevention of acute angina pectoris episodes. Methods: This was an open, self-paired comparative study performed at UNIFESO Medical School evaluating the clinical and laboratory results of treatment with propatyl nitrate in patients with chronic stable angina pectoris. Subjects received 10 mg of propatyl nitrate, at the dose of three sublingual tablets per day, to be taken at 8:00 A.M., 2:00 P.M., and 8:00 P.M. Subjects returned to the study center after 15 days of treatment for Visit 2 assessments, and at the end of the 30-day treatment period (Visit 3). Results: A total of 200 subjects were included in the study. There was a statistically significant reduction in blood pressure (p 0.0001) and heart rate (p = 0.0001), but no change in respiratory rate (p = 0.23). Laboratory results did not vary throughout the treatment period. There was no significant change from pretreatment in the SAQ Physical Limitation scale (p = 0.7415). The Angina Stability, Angina Frequency, and Treatment Satisfaction, and Quality of Life scales showed a significant improvement from pretreatment (p 0.0001). Adverse events were observed among 41 subjects at Visit 2 and 35 subjects at Visit 3. Conclusions: Propatyl nitrate was safe and effective in treating chronic stable angina pectoris over the course of the 30-day treatment period. Treatment with propatyl nitrate increased angina stability and reduced angina frequency while increasing treatment satisfaction and quality of life in the patient population evaluated.